Changes in Plasma GDF-15 and FGF-21 Levels in patient with morbid obesity after bariatric surgery

Changes in Plasma GDF-15 and FGF-21 Levels in patient with morbid obesity after bariatric surgery : A prospective cohort study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250212006

Enrollment

Registered

2025-02-12

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight reduction is requiring to hasten the burden of obesity and new hormones like GDF-15 and FGF-21 have role in reduce appetite and insufficient data in post bariatric surgery in morbid obesity. Weight reduction, Bariatric surgery Laparoscopic Roux-en-Y gastric bypass (RYGB) Laparoscopic sleeve gastrectomy (LSG) Growth Differentiation Factor 15 (GDF-15) Fibroblast growth factor 21 (FGF-21)

Interventions

One type of bariatric surgery to reduce size of stomach,One type of bariatric surgery to reduce size of stomach and bypass upper gastrointestinal tract

Active Comparator Procedure/Surgery,Active Comparator Procedure/Surgery

Laparoscopic sleeve gastrectomy (LSG),Laparoscopic Roux-en-Y gastric bypass (RYGB)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Morbid obesity patients in obesity clinic at King Chulalongkorn Memorial Hospital who has undergone bariatric surgery.

Exclusion criteria

Exclusion criteria: 1.Patients with congestive heart failure Newyork Heart Association 3-4 2.Patient with active cancer disease 3.Patient with severe illness/recent hospitalization before bariatric surgery 4.Severe malnutrition/ protein deprivation 5.Patients with severe psychiatric condition i.e., major depressive disorder, severe psychosis or 6.Binge eating disorder 7.Pregnancy and lactation 8.Unable or unwilling to return to follow up visits

Design outcomes

Primary

Measure	Time frame
Plasma GDF-15 at post bariatric surgery 6 month at 6 months post bariatric surgery ELISA (pg/ml)	—

Secondary

Measure	Time frame
Plasma GDF-15 level after bariatric surgery at 1 and 3 month At 1 and 3 months post bariatric surgery ELISA (pg/ml),Plasma FGF-21 level after bariatric surgery at 1,3 and 6 month At 1,3 and 6 months post bariatric surgery ELISA (pg/ml),How differences in change in GDF-15 and FGF-21 between laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy At 1,3 and 6 months post bariatric surgery ELISA (pg/ml),How differences in change in GDF-15 and FGF-21 hormone levels between diabetic patients and non-diabetic patients. At 1,3 and 6 months post bariatric surgery ELISA (pg/ml),Relationship between the changes in GDF-15 hormone levels after a 6-month period following bariatric surgery and the occurrence of diabetic remission. At 1,3 and 6 months post bariatric surgery ELISA (pg/ml)	—

Measure

Time frame

Plasma GDF-15 level after bariatric surgery at 1 and 3 month At 1 and 3 months post bariatric surgery ELISA (pg/ml),Plasma FGF-21 level after bariatric surgery at 1,3 and 6 month At 1,3 and 6 months post bariatric surgery ELISA (pg/ml),How differences in change in GDF-15 and FGF-21 between laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy At 1,3 and 6 months post bariatric surgery ELISA (pg/ml),How differences in change in GDF-15 and FGF-21 hormone levels between diabetic patients and non-diabetic patients. At 1,3 and 6 months post bariatric surgery ELISA (pg/ml),Relationship between the changes in GDF-15 hormone levels after a 6-month period following bariatric surgery and the occurrence of diabetic remission. At 1,3 and 6 months post bariatric surgery ELISA (pg/ml)

—

Countries

Thailand

Contacts

Public ContactKanokwan Kesornpatumanant

King Chulalongkorn Memorial Hospital

kanokwank0810@gmail.com0655879926

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026